S&P Futures
6,003.75 0.00 (0.00%) Dow Futures
43,918.00 +8.00 (+0.02%) Nasdaq Futures
21,221.00 -3.75 (-0.02%) Russell 2000 Futures
2,398.30 +2.60 (+0.11%) Crude Oil
72.05 -0.31 (-0.43%) Gold
2,709.10 +3.30 (+0.12%)
Nykode Therapeutics AS (5VB.F)
- GlobeNewswire
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe
OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona. The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particu
- GlobeNewswire
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”. The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the tr
